Quick Comparison
| ALCAR | Piracetam | |
|---|---|---|
| Half-Life | 4-5 hours | 4-5 hours |
| Typical Dosage | Standard: 500-2000 mg daily in 1-2 doses. For cognitive support: 1000-2000 mg daily. For neuropathy: 1500-3000 mg daily. Take in the morning — may be mildly stimulating. | Standard: 1200-4800 mg daily in 2-3 divided doses. Clinical studies commonly use 2400-4800 mg daily. The 'attack dose' protocol uses 4800 mg daily for the first week, then reduces to maintenance. |
| Administration | Oral (capsules, powder). Well-absorbed on an empty stomach. | Oral (powder, capsules, tablets). Highly bioavailable orally with nearly 100% absorption. |
| Research Papers | 9 papers | 10 papers |
| Categories |
Mechanism of Action
ALCAR
ALCAR crosses the blood-brain barrier via the organic cation transporter (OCTN2) more effectively than L-carnitine. In neurons, it is hydrolyzed by carnitine acetyltransferase to donate its acetyl group to coenzyme A, forming acetyl-CoA—which can then be used for acetylcholine synthesis via choline acetyltransferase, effectively providing raw material for the memory neurotransmitter. ALCAR also transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system for beta-oxidation and ATP production. ALCAR activates nerve growth factor (NGF) signaling, possibly through modulation of NGF receptor (TrkA) expression or downstream MAPK/ERK pathways. It has antioxidant properties, reducing lipid peroxidation in mitochondrial membranes and scavenging free radicals. These mechanisms support cognitive function and neuroprotection.
Piracetam
Piracetam modulates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-D-aspartate) glutamate receptors through positive allosteric modulation, enhancing excitatory neurotransmission without direct agonism. It increases membrane fluidity of neuronal phospholipid bilayers by reducing membrane microviscosity, which improves ion channel function and signal transmission. Piracetam enhances acetylcholine receptor density and turnover in the hippocampus, upregulating both muscarinic (M1) and nicotinic receptor expression. It potentiates the cholinergic system through increased high-affinity choline uptake. Additionally, piracetam improves cerebral blood flow via nitric oxide-dependent vasodilation and enhances oxygen utilization (glucose metabolism) in aged or hypoxic brain tissue, supporting mitochondrial function.
Risks & Safety
ALCAR
Common
Nausea, fishy body odor, restlessness, gastrointestinal discomfort.
Serious
May increase agitation in Alzheimer's patients. TMAO production may be a cardiovascular concern with chronic high doses.
Rare
Seizures in susceptible individuals, increased thyroid activity.
Piracetam
Common
Headache (often from insufficient choline intake), insomnia if taken late in the day, gastrointestinal discomfort.
Serious
Very rare — piracetam has an extremely favorable safety profile. May increase the effects of blood thinners.
Rare
Nervousness, agitation, weight gain.
Full Profiles
ALCAR →
Acetyl-L-Carnitine is an acetylated form of L-Carnitine that crosses the blood-brain barrier more effectively than regular L-Carnitine. In the brain, it donates its acetyl group for acetylcholine synthesis and supports mitochondrial fatty acid oxidation for energy. Used clinically for age-related cognitive decline, depression, and diabetic neuropathy.
Piracetam →
The original nootropic, synthesized in 1964 by Corneliu Giurgea who coined the term 'nootropic.' Piracetam modulates glutamate and acetylcholine neurotransmission to enhance memory, learning, and cognitive fluidity. Widely prescribed in Europe for cognitive decline and used globally as a cognitive enhancer. One of the most studied nootropics with decades of clinical data.